Published in PLoS One on July 01, 2016
The neutrophil-to-lymphocyte ratio: a narrative review. Ecancermedicalscience (2016) 0.81
Chitotriosidase, a marker of innate immunity, is elevated in patients with primary breast cancer. Cancer Biomark (2017) 0.75
Prognostic significance of neutrophil to lymphocyte ratio in ovarian cancer: evidence from 4,910 patients. Oncotarget (2017) 0.75
Prognostic role of neutrophil-lymphocyte ratio in nasopharyngeal carcinoma: A meta-analysis. PLoS One (2017) 0.75
Meta-analysis in clinical trials. Control Clin Trials (1986) 144.91
Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA (2000) 55.37
Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer (2014) 40.30
Immunity, inflammation, and cancer. Cell (2010) 28.27
Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96
Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics (2000) 19.26
Practical methods for incorporating summary time-to-event data into meta-analysis. Trials (2007) 14.51
Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol (2009) 9.41
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother (2008) 6.55
Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol (2008) 4.72
Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst (2014) 4.20
The role of increasing detection in the rising incidence of prostate cancer. JAMA (1995) 3.79
A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer (2011) 3.59
Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med (2005) 3.13
Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol (2009) 2.31
CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res (2013) 2.19
Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer (2014) 2.10
Rise in prostatic cancer incidence associated with increased use of transurethral resection. J Natl Cancer Inst (1990) 2.05
IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature (2015) 2.04
CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res (2007) 1.94
Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist (2008) 1.93
Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer (2014) 1.93
Tumor associated macrophages and neutrophils in cancer. Immunobiology (2013) 1.87
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Ann Oncol (2014) 1.75
Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol (2014) 1.72
Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods (2009) 1.48
High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy. Int J Urol (2015) 1.44
Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001-2007. Prostate Cancer (2012) 1.38
Prognostic role of NLR in urinary cancers: a meta-analysis. PLoS One (2014) 1.36
Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study. Prostate Cancer Prostatic Dis (2011) 1.17
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Ann Oncol (2014) 1.17
Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer (2014) 1.12
Association between systemic inflammatory markers and serum prostate-specific antigen in men without prostatic disease - the 2001-2008 National Health and Nutrition Examination Survey. Prostate (2014) 1.01
B lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretion. Cancer Immunol Immunother (2012) 0.98
Neutrophil-mediated tumour angiogenesis: subversion of immune responses to promote tumour growth. Semin Cancer Biol (2013) 0.98
Antigen-nonspecific activation of CD8+ T lymphocytes by cytokines: relevance to immunity, autoimmunity, and cancer. Arch Immunol Ther Exp (Warsz) (2008) 0.94
Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer. Clin Genitourin Cancer (2015) 0.94
Neutrophil-to-lymphocyte ratio may be associated with the outcome in patients with prostate cancer. Springerplus (2015) 0.93
Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Clin Genitourin Cancer (2013) 0.91
Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer. APMIS (2012) 0.89
Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment. Mediators Inflamm (2016) 0.89
Neutrophil count is associated with survival in localized prostate cancer. BMC Cancer (2015) 0.89
Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel. Int Urol Nephrol (2014) 0.88
Infiltration of CD8+ lymphocytes is an independent prognostic factor of biochemical failure-free survival in prostate cancer. Prostate (2014) 0.88
Significance of IL-6 in the transition of hormone-resistant prostate cancer and the induction of myeloid-derived suppressor cells. J Mol Med (Berl) (2012) 0.87
High preoperative neutrophil-lymphocyte ratio predicts biochemical recurrence in patients with localized prostate cancer after radical prostatectomy. World J Urol (2015) 0.84
Pretreatment Neutrophil-to-Lymphocyte Ratio: A Predictor of Advanced Prostate Cancer and Biochemical Recurrence in Patients Receiving Radical Prostatectomy. Medicine (Baltimore) (2015) 0.83
Prostate cancer: measuring PSA. Intern Med J (2014) 0.82
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer: A Systematic Review and Meta-analysis. Medicine (Baltimore) (2016) 0.81
Pretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancer. BMC Cancer (2016) 0.80
Increased autophagy sustains the survival and pro-tumourigenic effects of neutrophils in human hepatocellular carcinoma. J Hepatol (2014) 0.77